The Possible Role of NLRP3 Inflammasome in Depression and Myocardial Infarction Comorbidity.
Erensu BaysakCagan YildirimNurten SayarMustafa Kemal SayarAngelos HalarisFeyza AriciogluPublished in: Journal of personalized medicine (2023)
It is well-established that cardiovascular disease and depression are highly comorbid. This study aimed to assess the possible role of the NOD-like receptor protein 3 (NLRP3) inflammasome pathway and the high-sensitivity C-reactive protein ( hs CRP) in patients with incident myocardial infarction in the presence or absence of depression. Sixty-eight consecutive patients with incident ST-elevation myocardial infarction and twenty healthy subjects were included. The patients were assessed using the Structured Clinical Interview for DSM-5 Disorders-Clinician Version during their 1-4-day-long hospitalization and were divided into two groups: with and without comorbid depression. Blood samples for the determination of NLRP3, interleukin-18 (IL-18), interleukin-1β (IL-1β), and hs CRP levels were analyzed using ELISA. NLRP3, IL-1β, IL-18, and hs CRP levels were significantly higher in myocardial infarction patients compared to the healthy group ( p = 0.02, p < 0.001, p < 0.001, and p < 0.001, respectively). No significant difference was found between the myocardial groups with and without depression. However, in the logistic regression analysis, the NLRP3 variable in myocardial infarction patients was found to have a significant contribution to the likelihood of depression ( p = 0.015, OR = 1.72, and CI = 1.11-2.66). The likelihood of depression is associated with increasing NLRP3 levels in myocardial infarction patients. However, this potential role should be further explored in a larger sample.
Keyphrases
- nlrp inflammasome
- end stage renal disease
- cardiovascular disease
- ejection fraction
- newly diagnosed
- depressive symptoms
- heart failure
- chronic kidney disease
- left ventricular
- prognostic factors
- peritoneal dialysis
- sleep quality
- type diabetes
- metabolic syndrome
- patient reported outcomes
- small molecule
- cardiovascular events